BAJAJ BROKING

Notification close image
No new Notification messages
card image
🚨 TRADING HOLIDAY 🚨
The NSE and BSE will remain closed for trading and settlement on Wednesday, August 27, 2025, on account of Ganesh Chaturthi.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

0

530317

GODAVARI

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

GODAVARI DRUGS LTD. Share Price Update

As of the latest trading session, GODAVARI DRUGS LTD. share price is currently at ₹ 83.28, which is up by ₹ 0.36 from its previous closing. Today, the stock has fluctuated between ₹ 81.65 and ₹ 84.90. Over the past year, GODAVARI DRUGS LTD. has achieved a return of -25.37 %. In the last month alone, the return has been -5.65 %. Read More...

Investment Returns

Over 1 Month -5.65% Over 3 Months -15.11% Over 6 Months -5.08% Over 1 Year -25.37%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

GODAVARI DRUGS LTD. fundamentals


  • Market cap (Cr)

  • P/E Ratio (TTM)

  • Beta

  • Book Value / share

  • Return on equity

    %

  • EPS (TTM)

  • Dividend yield

    %

  • Net profit/quarter (Cr)

info icon alternate text
  • Market cap (Cr)

    62.70

  • P/E Ratio (TTM)

    16.48

  • Beta

    0.82

  • Book Value / share

    57.56

  • Return on equity

    15.33%

  • EPS (TTM)

    5.03

  • Dividend yield

    %

  • Net profit/quarter (Cr)

    1.04

info icon alternate text

GODAVARI DRUGS LTD. Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 23.81
Operating Expense 22.52
Net Profit 1.04
Net Profit Margin (%) 4.36
Earnings Per Share (EPS) 1.38
EBITDA 2.90
Effective Tax Rate (%) 20.00
Particulars MAR 2025 (Values in Cr)
Revenue 25.50
Operating Expense 24.16
Net Profit 0.89
Net Profit Margin (%) 3.49
Earnings Per Share (EPS) 1.19
EBITDA 3.21
Effective Tax Rate (%) 38.19
Particulars DEC 2024 (Values in Cr)
Revenue 29.55
Operating Expense 28.73
Net Profit 0.77
Net Profit Margin (%) 2.60
Earnings Per Share (EPS) 1.02
EBITDA 2.67
Effective Tax Rate (%) 16.30
Particulars SEP 2024 (Values in Cr)
Revenue 26.09
Operating Expense 24.85
Net Profit 1.09
Net Profit Margin (%) 4.17
Earnings Per Share (EPS) 1.45
EBITDA 2.91
Effective Tax Rate (%) 12.80
Particulars JUN 2024 (Values in Cr)
Revenue 32.21
Operating Expense 30.97
Net Profit 1.63
Net Profit Margin (%) 5.06
Earnings Per Share (EPS) 2.17
EBITDA 4.00
Effective Tax Rate (%) 18.90
Particulars MAR 2025 (Values in Cr)
Revenue 113.35
Operating Expense 108.70
Net Profit 4.38
Net Profit Margin (%) 3.86
Earnings Per Share (EPS) 5.82
EBITDA 12.80
Effective Tax Rate (%) 22.20
Particulars MAR 2024 (Values in Cr)
Revenue 156.71
Operating Expense 150.32
Net Profit 5.55
Net Profit Margin (%) 3.54
Earnings Per Share (EPS) 7.37
EBITDA 13.83
Effective Tax Rate (%) 19.79
Particulars MAR 2023 (Values in Cr)
Revenue 159.62
Operating Expense 155.58
Net Profit 3.79
Net Profit Margin (%) 2.37
Earnings Per Share (EPS) 5.03
EBITDA 10.79
Effective Tax Rate (%) 23.32
Particulars MAR 2022 (Values in Cr)
Revenue 161.11
Operating Expense 154.35
Net Profit 5.25
Net Profit Margin (%) 3.25
Earnings Per Share (EPS) 6.97
EBITDA 11.56
Effective Tax Rate (%) 25.35
Particulars MAR 2021 (Values in Cr)
Revenue 122.67
Operating Expense 117.38
Net Profit 4.13
Net Profit Margin (%) 3.36
Earnings Per Share (EPS) 5.48
EBITDA 10.24
Effective Tax Rate (%) 27.67
Particulars MAR 2024 (Values in Cr)
Book Value / Share 51.74
ROE % 15.33
ROCE % 14.14
Total Debt to Total Equity 1.29
EBITDA Margin 8.83
Particulars MAR 2023 (Values in Cr)
Book Value / Share 44.38
ROE % 12.02
ROCE % 14.37
Total Debt to Total Equity 0.93
EBITDA Margin 6.77
Particulars MAR 2022 (Values in Cr)
Book Value / Share 39.35
ROE % 19.44
ROCE % 18.12
Total Debt to Total Equity 0.99
EBITDA Margin 7.18
Particulars MAR 2021 (Values in Cr)
Book Value / Share 32.38
ROE % 18.50
ROCE % 17.34
Total Debt to Total Equity 1.30
EBITDA Margin 8.36
Particulars MAR 2020 (Values in Cr)
Book Value / Share 26.90
ROE % 10.22
ROCE % 11.55
Total Debt to Total Equity 1.29
EBITDA Margin 6.65
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2.62
Total Assets 134.75
Total Liabilities 134.75
Total Equity 38.96
Share Outstanding 7530500
Price to Book Ratio 1.80
Return on Assets (%) 4.11
Return on Capital (%) 5.87
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 3.08
Total Assets 121.43
Total Liabilities 121.43
Total Equity 33.41
Share Outstanding 7530500
Price to Book Ratio 1.71
Return on Assets (%) 3.11
Return on Capital (%) 5.66
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.27
Total Assets 101.41
Total Liabilities 101.41
Total Equity 29.63
Share Outstanding 7530500
Price to Book Ratio 1.66
Return on Assets (%) 5.17
Return on Capital (%) 10.5
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.63
Total Assets 91.13
Total Liabilities 91.13
Total Equity 24.38
Share Outstanding 7530500
Price to Book Ratio 1.41
Return on Assets (%) 4.52
Return on Capital (%) 7.87
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1.42
Total Assets 83.91
Total Liabilities 83.91
Total Equity 20.25
Share Outstanding 7530500
Price to Book Ratio 0.43
Return on Assets (%) 2.38
Return on Capital (%) 4.32
Particulars MAR 2024 (Values in Cr)
Net Income 13.83
Cash from Operations 19.43
Cash from Investing -13.22
Cash from Financing -5.65
Net change in Cash -0.46
Free Cash Flow 32.63
Particulars MAR 2023 (Values in Cr)
Net Income 10.80
Cash from Operations 14.36
Cash from Investing -8.63
Cash from Financing -3.77
Net change in Cash 0.80
Free Cash Flow 23.66
Particulars MAR 2022 (Values in Cr)
Net Income 11.56
Cash from Operations 13.00
Cash from Investing -4.97
Cash from Financing -5.62
Net change in Cash 0.63
Free Cash Flow 18.25
Particulars MAR 2021 (Values in Cr)
Net Income 10.23
Cash from Operations 2.90
Cash from Investing -1.25
Cash from Financing 0.13
Net change in Cash 0.21
Free Cash Flow 4.57
Particulars MAR 2020 (Values in Cr)
Net Income 6.36
Cash from Operations 6.63
Cash from Investing -6.68
Cash from Financing 0.33
Net change in Cash -0.09
Free Cash Flow 13.52
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 33.30 13.59 1.82 255.19 30.00 / 69.75
BLISS GVS PHARMA LTD 159.00 15.73 1.59 1677.41 105.05 / 190.65
CIPLA LTD 1601.10 23.98 4.14 129329.50 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 323.75 9.12 2.62 952.83 219.00 / 449.00
GLAXOSMITHKLINE PHARMA LT 2799.20 50.08 24.30 47420.14 1924.30 / 3515.95
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 34.33 18.66 5.42 263.08 30.00 / 69.75
AMRUTAJAN HEALTH LTD 701.35 37.19 6.20 2027.65 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8431.65 99.68 27.36 21079.13 6222.35 / 10653.05
BLISS GVS PHARMA LTD 161.45 24.13 1.60 1703.26 105.05 / 190.65

GODAVARI DRUGS LTD. Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
83.28 0.44 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 83.60
  • 26 Days 85.50
  • 10 Days 84.10
  • 50 Days 87.70
  • 12 Days 84.20
  • 100 Days 91.30
  • 20 Days 84.90
  • 200 Days 96.30
83.80 PIVOT

First Support

82.61

First Resistance

84.61

Second Support

81.80

Second Resistance

85.80

Third Support

80.61

Third Resistance

86.61

RSI

42.34

ADX

17.01

MACD

-1.28

Williams % R

-77.30

Commodity Channel Index (CCI)

-54.22

Date

2025-08-22

Week

3344.00

Same Day

3339.00

Month

2604.00

1 Year

0.83

3 Year

0.42

Over 1 Month

-5.65%

down

Over 1 Year

-25.37%

down

Over 3 Months

-15.11%

down

Over 3 Years

6.62%

down

Over 6 Months

-5.08%

down

Over 5 Years

15.80%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

GODAVARI DRUGS LTD. shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Name Shares Category

News

Left Arrow
Right Arrow

GODAVARI DRUGS LTD. corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
[-] [-] [-] [-] [-]
Ex-Date Ex-Bonus Ratio
[-] [-] [-]
Ex-Date Old FV NEW FV Record Date
[-] [-] [-] [-]

GODAVARI DRUGS LTD. Share Price

Godavari Drugs Limited is engaged in the business of manufacture of Active Pharmaceutical Ingredients (API) and drug intermediates, through its manufacturing facility at Nanded, Maharashtra, India.. Sulphamethoxazole (SMX), the main product of the company, is a widely used anti-bacterial drug enjoying good export demand.

The Company incorporated in December, 1987, has multiple production blocks for API's, drug intermediates and fine chemicals.

The company has expanded its SMX capacity from 540 tpa to 720 tpa, integrating backward into the manufacture of drug intermediates, sulphamethoxide (cap.: 450 tpa) and diethyl oxalate, DEO (cap.: 750 tpa), and diversifying into the manufacture of trimetroprim, TMP (cap.: 144 tpa).

The diversification into TMP is beneficial as SMX and TMP are used in combination to treat a wide variety of infections. The backward integration into SMO and DEO will enhance value-addition. In fact, Siris and Chemox Chemicals, both having good capacities of SMX, have recently gone in for the production of SMO.

In 2000 the company introduced 'Pyrazyamide' in the market. Since the product is being well accepted in the market the company is planning to increase the capacity of 'Pyrazyamide' of 180 TPA and have also finalised on other products Cislactum,which is a intermediate used to produce Diltiazem an anti anginal drug.

The Company combine their intrinsic strengths in chemistry with capabilities of process development, right from laboratory scale to
pilot scale in pilot plant and finally manufacturing at the commercial scale in manufacturing facilities, which are in line with cGMP requirements. A combination of chemistry knowledge, with engineering strengths, along with good analytical backup enables Godavari Drugs to develop, scale, up and manufacture products right from laboratory to commercial scale.

Parent organization Indian Private
NSE symbol [-]
Founded 1987
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Godavari Drugs Ltd?

Answer Field

Godavari Drugs Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 83.28 as on Aug 26 2025 03:18 PM.

What is the Market Cap of Godavari Drugs Ltd Share?

Answer Field

The market cap of Godavari Drugs Ltd for NSE ₹ 0.00 & for BSE ₹ 62.70 as on Aug 26 2025 03:18 PM.

What is the 52 Week High and Low of Godavari Drugs Ltd?

Answer Field

The 52 Week High and Low of Godavari Drugs Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 155.00 and ₹ 79.00.

What is 1 year return for Godavari Drugs Ltd?

Answer Field

The 1 year returns on the stock has been -25.37%.

What is the P/E Ratio of Godavari Drugs Ltd Share?

Answer Field

As on Aug 26 2025 03:18 PM the price-to-earnings (PE) ratio for Godavari Drugs Ltd share is 16.48.

What is the PB ratio of Godavari Drugs Ltd Share?

Answer Field

As on Aug 26 2025 03:18 PM, the price-to-book (PB) ratio for Godavari Drugs Ltd share is 57.56.

How to Buy Godavari Drugs Ltd Share?

Answer Field

You can trade in Godavari Drugs Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Godavari Drugs Ltd Share on Bajaj Broking App?

Answer Field

To buy Godavari Drugs Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Godavari Drugs Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91